Rapamune and Cholecystitis - a phase IV clinical study of FDA data

Summary:

Cholecystitis is reported as a side effect among people who take Rapamune (sirolimus), especially for people who are male, 40-49 old, have been taking the drug for 1 - 6 months also take Prednisone,.

The phase IV clinical study analyzes which people have Cholecystitis when taking Rapamune. It is created by eHealthMe based on reports of 13,732 people who have side effects when taking Rapamune from the FDA, and is updated regularly.

What is Rapamune?

Rapamune has active ingredients of sirolimus. It is often used in kidney transplant. eHealthMe is studying from 13,848 Rapamune users. Check the latest studies of Rapamune.

What is Cholecystitis?

Cholecystitis (infection of gallbladder) is found to be associated with 1,167 drugs and 1,218 conditions by eHealthMe. Check the latest studies of Cholecystitis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

13,732 people reported to have side effects when taking Rapamune.
Among them, 21 people (0.15%) have Cholecystitis.

Among these 21 people:

How long have people been on Rapamune when they have Cholecystitis? *

What is the gender of people who have Cholecystitis when taking Rapamune? *

female: 40 %
male: 60 %

What is the age of people who have Cholecystitis when taking Rapamune? *

What are other drugs people take besides Rapamune? *

What are other side effects people have besides Cholecystitis? *

Thrombocytopenia (decrease of platelets in blood): 8 people, 38.10%
Sepsis (a severe blood infection that can lead to organ failure and death): 8 people, 38.10%
Pneumonia: 8 people, 38.10%
Atelectasis (partial or complete collapse of the lung): 6 people, 28.57%
Marrow Hyperplasia (increased bone marrow): 5 people, 23.81%
Pleural Fibrosis (formation of fibrous tissue in lung): 4 people, 19.05%
Intestinal Obstruction: 4 people, 19.05%
Diarrhea: 4 people, 19.05%
Eosinophilia (eosinophil count in the peripheral blood exceeds): 4 people, 19.05%
Leukopenia (less number of white blood cells in blood): 4 people, 19.05%

* Approximation only. Some reports may have incomplete information.

Do you take Rapamune and have Cholecystitis?

- Check whether Cholecystitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rapamune:

Rapamune (13,848 reports)

Cholecystitis treatments and more:

Cholecystitis (16,481 reports)

Browse all side effects of Rapamune:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cholecystitis:

Cholecystitis (1,167 drugs)

Browse all the conditions that are associated with Cholecystitis:

Cholecystitis (1,218 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sirolimus (the active ingredients of Rapamune) and Rapamune (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.